The BNF for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.
BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.
Sales and UpgradesContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge
Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 6 significant changes, 1 dose change and 1 deleted preparation.
Significant Changes:
• Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use [MHRA/CHM advice].
• COVID-19: updated guidance.
• COVID-19 vaccines: updated guidance in-line with Public Health England/UK Health Security Agency recommendations.
• Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
• Phenobarbital: updated information on the available oral solutions and advice from the RCPCH/NPPG can be found in the prescribing and dispensing section of the Phenobarbital monograph.
• Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist [MHRA/CHM advice].
Dose Changes:
• Adrenaline/epinephrine [update to dosing for acute anaphylaxis].
Deleted Preparations: Tacni® [tacrolimus].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 8 significant changes, 2 dose changes, 1 classification change and 5 new monographs.
Significant Changes:
• Acne: updated guidance on management.
• Chloral hydrate, cloral betaine (Welldorm®): restriction of paediatric indication [MHRA/CHM advice].
• COVID-19 vaccine: title changed to COVID-19 vaccines.
• COVID-19 vaccines: updated guidance in-line with Public Health England/UK Health Security Agency recommendations.
• Nausea and labyrinth disorders: updated guidance on the management of nausea and vomiting during pregnancy.
• Rosacea and Acne: title changed to Rosacea.
• Tofacitinib (Xeljanz®): new measures to minimise risk of major adverse cardiovascular events and malignancies [MHRA/CHM advice].
• Type 1 diabetes: updated guidance on Recommended insulin regimens.
Dose Changes:
• Chloral hydrate [update to dosing information for short-term treatment of severe insomnia].
• Pyridostigmine bromide [update to dosing for myasthenia gravis in neonates and children].
Classification Changes:
• Minoxidil [primary classification changed to Potassium-channel openers].
New Monographs:
• Acarizax® [house dust mite extract].
• Cibinqo® [abrocitinib].
• Koselugo® [selumetinib].
• Orladeyo® [berotralstat].
• Xeljanz® [tofacitinib].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 3 significant changes, 6 dose changes, 2 new monographs and 1 deleted monograph.
Significant Changes:
• Antihistamines, allergen immunotherapy and allergic emergencies: updated guidance for the management of anaphylaxis.
• Gastro-intestinal system infections, antibacterial therapy: updated guidance on the management of Clostridioides difficile infection.
• Topical corticosteroids: information on the risk of topical steroid withdrawal reactions [MHRA/CHM advice] (advice in alclometasone dipropionate, beclometasone dipropionate, benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide, betamethasone, cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate, cinchocaine with hydrocortisone, cinchocaine with prednisolone, clobetasol propionate, diflucortolone valerate, fludroxycortide, fluocinolone acetonide, fluticasone, hydrocortisone, hydrocortisone with lidocaine; see example in hydrocortisone).
Dose Changes:
• Adrenaline/epinephrine [update to dosing for emergency treatment of acute anaphylaxis].
• COVID-19 vaccine [update to dosing for immunisation against COVID-19].
• Dolutegravir [update to dosing for the treatment of HIV infection].
• Etravirine [update to age and weight range for HIV infection].
• Sapropterin dihydrochloride [update to age range for phenylketonuria].
• Vancomycin [update to dosing for Clostridioides difficile infection].
New Monographs:
• Liraglutide.
• Ryaltris® [mometasone furoate with olopatadine].
Deleted Monographs: Tinidazole.
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 7 significant changes, and 1 new monograph.
Significant Changes:
• COVID-19 vaccine: updated guidance in-line with Public Health England recommendations.
• Diabetic hyperglycaemic emergencies: updated guidance.
• Diabetic Ketoacidosis: title changed to Diabetic hyperglycaemic emergencies.
• Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.
• Influenza vaccine: updated guidance in-line with Public Health England recommendations.
• Remdesivir: update to treatment duration.
• Trientine dihydrochloride: name change to trientine, and update to dosing for Wilson’s disease.
New Monographs:
• Adakveo® [crizanlizumab].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 4 significant changes and 3 new monographs.
Significant Changes:
• Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years [MHRA/CHM advice].
• Migraine: updated guidance on preventative migraine treatment.
• Neonatal infection, antibacterial therapy: new guidance on management.
• Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic [MHRA/CHM advice] (advice in acitretin, isotretinoin; see example in isotretinoin).
New Monographs:
• Evrysdi® [risdiplam].
• Fintepla® [fenfluramine].
• Taltz® [ixekizumab].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 5 significant changes, 1 dose change, 2 new monographs, 2 new preparations and 1 deleted monograph.
Significant Changes:
• Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) [MHRA/CHM advice] (advice in ipilimumab, pembrolizumab; see example in ipilimumab).
• COVID-19 vaccine: reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines.
• Immunoglobulins: updated guidance in-line with Public Health England recommendations for the use of immunoglobulin for tetanus infection and prophylaxis.
• Prescribing in renal impairment: updated guidance.
• Tetanus vaccine: updated guidance in-line with Public Health England recommendations.
Dose Change:
• Valganciclovir [removal of dose equivalence statement].
New Monographs:
• Dificlir® [fidaxomicin].
• Keytruda® [pembrolizumab].
New Preparations: Fixkoh Airmaster® [fluticasone with salmeterol]; Kigabeq® [vigabatrin].
Deleted Monograph: Tetrahydrobiopterin.
For further details on changes in the BNF for Children click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
